Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Oral Cavity Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma · Recurrent Paranasal Sinus Squamous Cell Carcinoma · Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 · Stage III Hypopharyngeal Carcinoma AJCC v8 · Stage III Laryngeal Cancer AJCC v8 · Stage III Lip and Oral Cavity Cancer AJCC v8 · Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage III Sinonasal Cancer AJCC v8 · Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 · Stage IVA Hypopharyngeal Carcinoma AJCC v8 · Stage IVA Laryngeal Cancer AJCC v8 · Stage IVA Lip and Oral Cavity Cancer AJCC v8 · Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IVA Sinonasal Cancer AJCC v8 · Stage IVB Hypopharyngeal Carcinoma AJCC v8 · Stage IVB Laryngeal Cancer AJCC v8 · Stage IVB Lip and Oral Cavity Cancer AJCC v8 · Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IVB Sinonasal Cancer AJCC v8 · Unresectable Head and Neck Squamous Cell Carcinoma · Unresectable Hypopharyngeal Squamous Cell Carcinoma · Unresectable Laryngeal Squamous Cell Carcinoma · Unresectable Oral Cavity Squamous Cell Carcinoma · Unresectable Oropharyngeal Squamous Cell Carcinoma · Unresectable Paranasal Sinus Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UPMC Hillman Cancer Center LAO, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Yvonne M. Mowery) · yvm3@pitt.edu · 919-408-9981
Contact: Principal Investigator (Yvonne M. Mowery)

Study leads

Yvonne M Mowery
Principal Investigator
UPMC Hillman Cancer Center LAO

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Gilbert, United States · Peoria, United States

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary

Abroad (travel likely)RecruitingPHASE1

Tampa, United States · Chicago, United States

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

Abroad (travel likely)RecruitingEARLY_PHASE1

Atlanta, United States

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Locally Recurrent Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States